Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 9:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–8 of 8 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Aura Biosciences Clear all
Active, not recruiting No phase listed Observational

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

NCT03941379
View directory record Official record
Conditions
Choroidal Melanoma, Indeterminate Lesions of Eye
Interventions
Not listed
Lead sponsor
Aura Biosciences
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
16
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 6, 2026, 9:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study in Subjects With Small Primary Choroidal Melanoma

NCT03052127
View directory record Official record
Conditions
Uveal Melanoma, Ocular Melanoma, Choroidal Melanoma
Interventions
Light-activated AU-011, Laser Activation
Drug · Device
Lead sponsor
Aura Biosciences
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
13
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 6, 2026, 9:28 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

NCT06007690
View directory record Official record
Conditions
Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
Interventions
Bel-sar, Suprachoroidal Microinjector, Infrared Laser, Sham Infrared Laser, Sham Microinjector
Drug · Device
Lead sponsor
Aura Biosciences
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
32
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 6, 2026, 9:28 AM EDT
Completed Phase 2 Interventional

Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

NCT04417530
View directory record Official record
Conditions
Uveal Melanoma, Ocular Melanoma, Choroidal Melanoma
Interventions
AU-011, Suprachoroidal Microinjector, PDT Laser
Drug · Device
Lead sponsor
Aura Biosciences
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
22
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 6, 2026, 9:28 AM EDT
Active, not recruiting Phase 1 Interventional

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

NCT05483868
View directory record Official record
Conditions
Non-muscle-invasive Bladder Cancer, NMIBC, Non-Muscle Invasive Bladder Carcinoma, Non-Muscle Invasive Bladder Neoplasms, Non-Muscle Invasive Bladder Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions
AU-011, AU-011 in Combination with Medical Laser Adminstration, AU-011 in Combination with Medical Laser Administration
Drug · Combination Product
Lead sponsor
Aura Biosciences
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
13
States / cities
Little Rock, Arkansas • Los Angeles, California • Santa Monica, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 6, 2026, 9:28 AM EDT
Terminated No phase listed Observational

Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)

NCT05266430
View directory record Official record
Conditions
Choroidal Melanoma, Indeterminate Lesions
Interventions
Standard of Care, AU-011
Other · Drug
Lead sponsor
Aura Biosciences
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Royal Oak, Michigan • Portland, Oregon • Greenville, South Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2023 · Synced Oct 6, 2026, 9:28 AM EDT
Enrolling by invitation No phase listed Observational

A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma

NCT07338968
View directory record Official record
Conditions
Choroidal Melanoma, Indeterminate Lesions
Interventions
Observational
Other
Lead sponsor
Aura Biosciences
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
10
States / cities
Sacramento, California • Ann Arbor, Michigan • Rochester, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 6, 2026, 9:28 AM EDT
Recruiting Phase 2 Interventional

Suprachoroidal Administration in Subjects With Metastases to the Choroid

NCT06643884
View directory record Official record
Conditions
Eye Cancer, Primary Cancer
Interventions
AU-011, SCS Microinjector, Laser
Drug · Device
Lead sponsor
Aura Biosciences
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
10
States / cities
Palo Alto, California • Miami, Florida • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 6, 2026, 9:28 AM EDT